Retatrutide is a next-generation investigational peptide compound designed to act as a triple agonist at GLP-1, GIP, and glucagon receptors. As a research molecule, it has demonstrated significant promise in preclinical and early clinical studies related to metabolic modulation, weight regulation, and glycemic control pathways.
This compound is offered as a lyophilized powder in sterile, unlabeled glass vials to ensure purity and versatility in research settings. Our 10-vial research kits are produced under stringent quality control protocols and are independently batch-tested for identity and purity.
Each vial is intended for in vitro use only. Not for human consumption. Not for therapeutic or diagnostic purposes.
